Tools   Select Another Resource Report Type

http://www.knhi.zks.uni-leipzig.de/en/Research/SP03/

The goal of this project is the creation of an extensive biomaterials bank. Materials (blood, serum, plasma, DNA) from all patients who participate in studies in the network will be collected for this purpose. The objective is a consistently high quality standard for the processing, storage and management of all samples. The biomaterials bank is an investment in the future by the network. It enables the competence network and the research community in general to acquire new scientific knowledge about the development, progression and prognosis of the different forms of heart failure. Each time a patient is documented in a study in the competence network, blood (EDTA whole blood and serum) is drawn from the patient, sent by post to the central biomaterials bank and processed there in the central incoming sample laboratory according to specified standards. In the first two subsidization periods, a total of 100,000 samples from approximately 10,000 patients was documented and processed (aliquoting, DNA extraction). These samples are stored in climate-controlled rooms used especially for this purpose at the biomaterial bank of the Experimental and Clinical Research Center (ECRC) in Berlin-Buch at temperatures between -20 and -80 degrees C. As the central infrastructure project for all samples, the biomaterials bank is deeply involved in the networking. There are also intensive collaborations with other competence networks (e.g. the Competence Network for Congenital Heart Defects) and biobanks. The biomaterial bank of the Heart Failure Competence Network also participates in domestic and European pilot projects for networking biomaterial banks (BBMRI, ESFRI, etc.). The goal of these projects is to develop uniform methods for sample processing and use.

Proper citation: Central Biomaterial Bank - German Heart Failure Network (RRID:SCR_004667) Copy   

•   Source: SciCrunch Registry

http://www.mnbb.org/

The Michigan Neonatal Biobank (Biobank) is a storage and management facility for The Michigan Department of Community Health''s archive of dried blood spot cards. A 501(c)3 non-profit charitable organization, the Biobank is contracted to serve as the repository for storage and management of the samples in a temperature controlled facility at Wayne State University''s Biobanking Center of Excellence in Tech Town. The Biobank''s roots are planted in the State''s Newborn Screening Program which began in 1965 in the Department of Community Health. Newborn screening is a public health program required by Michigan law to find babies with rare but serious disorders that require early treatment. A few drops of blood taken from the baby''s heel are sent to the State Public Health Laboratory and are tested for 49 disorders. Each year more than 200 Michigan babies are found to have a disorder detected by Newborn Screening. Once screening in the State laboratory is complete, residual dried blood spot samples that are no longer needed for testing are each assigned a unique code which assures anonymity for the sample and its donor. The samples are then sent for storage in the Michigan Neonatal Biobank.

Proper citation: Michigan Neonatal Biobank (RRID:SCR_004541) Copy   

•   Source: SciCrunch Registry

http://www.addgene.org/vector-database/

Vector database is a digital collection of vector backbones assembled from publications and commercially available sources. This is a free resource for the scientific community that is compiled by Addgene. Only the plasmids deposited at Addgene are available for purchase through this website.

Proper citation: Vector Database (RRID:SCR_005907) Copy   

•   Source: SciCrunch Registry

http://www.interpore.com/

Biomet and Interpore Cross are on the cutting edge of technology in the orthopedic biomaterials market. Our focus is developing and providing truly innovative products, which meet the rapidly expanding needs of orthopedic surgeons both today and in the future. Our Pro Osteon resorbable bone graft material is derived from an abundant non-decorative coral. Pro Osteon is available in a selection of fully resorbable sterile granules and blocks, in a variety of shapes and sizes. Our InterGro DBM products combine the osteoinductivity of DBM with a natural, non-soluble carrier that won''t wash away, delivering a unique bone graft that offers superior handling and performance characteristics. This highly-moldable composite graft can be easily formed to fit any shape fracture or defect.

Proper citation: Interpore Cross International (RRID:SCR_004776) Copy   

•   Source: SciCrunch Registry

http://darwin.di.uminho.pt/anote2/wiki/index.php/Main_Page

THIS RESOURCE IS NO LONGER IN SERVICE. Documented September 18, 2017. Text Mining platform that copes with major Information Retrieval and Information Extraction tasks and promotes multi-disciplinary research. It aims to provide support to three different usage roles: biologists, text miners and application developers. The workbench supports the retrieval, processing and annotation of documents as well as their analysis at different levels.

Proper citation: (at)Note (RRID:SCR_005342) Copy   

•   Source: SciCrunch Registry

http://ki.se/ki/jsp/polopoly.jsp?d=29332&a=103566&l=en

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on May 3rd, 2023. The ICAP - Integrated analysis of prostate cancer study aims at identifying a set of biomarkers with high prognostic value for prostate cancer progression. These biomarkers will be used to customize treatment and to identify patients with high risk of recurrent disease. Sample types: * EDTA whole blood * DNA Number of sample donors: 505 (sample collection completed)

Proper citation: ICAP - Integrated analysis of prostate cancer (RRID:SCR_006035) Copy   

•   Source: SciCrunch Registry

http://ki.se/ki/jsp/polopoly.jsp?d=29332&a=103538&l=en

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 23, 2016. Libro-1 is a study with the overall aim to identify prognostic factors for breast cancer. The study comprise women in the Stockholm-Gotland region that were diagnosed with breast cancer between the years 2001-2008. Register data (tumor characteristics and treatment), lifestyle factors and blood samples have been collected from the participants.

Proper citation: LIBRO-1: Individualized prediction and prevention of breast cancer (RRID:SCR_006036) Copy   

•   Source: SciCrunch Registry

http://cancer.case.edu/research/sharedresources/tissue/services/

A combined tissue bank and core facility which provides annotated human tissue samples for research purposes. The facility also offers high quality tissue procurement, tissue microarray, histology, immunohistochemistry, photomicroscopy, and laser capture microdissection services for both human and animal tissues to biomedical investigators conducting non-clinical research studies. The TPHC offers instruction to researchers on how to incorporate human tissue into research activities and how to work within the boundaries of patient confidentiality and other regulatory issues. The purpose of the TPHC is to provide tissue collection and processing services to intramural and extramural researchers studying cancer and other diseases. Normal, diseased, benign and malignant tissues are obtained, and matched normal adjacent tissues and tissues from different organ sites from the same donor can also be provided when available. Tissue samples are prepared according to user-specified protocols and can be fresh in a medium of choice, fixed in formalin, quick frozen in the vapor phase of liquid nitrogen or snap-frozen by plunging the sample into liquid nitrogen. Frozen tissues are held in the vapor phase of the liquid nitrogen. Tissues can also be embedded, cut and mounted on slides, and stained upon request. Tissue Microarray (TMA) services are offered for the design and construction of TMAs meeting specific project needs. Basic demographic data (age, race, gender) and histopathologic data from Surgical Pathology Reports are provided by the TPHC with the tissues.

Proper citation: Case Western Reserve Tissue Procurement and Histology Core Facility (RRID:SCR_005344) Copy   

•   Source: SciCrunch Registry

http://www.procap.ki.se/procap_studie_info.htm

PROCAP is a study of the importance of lifestyle and genetic factors in the progression of localized cancer of the prostate. Our study hypothesis is that the likelihood of disease recurrence of prostate cancer is modified or determined by genetic variation in the human genome and/or lifestyle factors. To be able to test our hypothesis, we are using a large, population-based cohort of men with localized prostate cancer in Sweden, recruited in 1997-2002, from which detailed clinical information and data on progression already have been collected. From this cohort, we are collecting lifestyle data and blood samples from 8,500 men. If men with progressive prostate cancer could be identified on their genetic make-up, they could be given additional therapies targeted specifically at prostate cancer progression or monitored even more frequently so that progressions could be treated even earlier. If lifestyle factors are important, these results have an impact on recommendations given to men with newly diagnosed prostate cancer. In the study, we are asking the study persons to fill in an Internet-based questionnaire focusing on diet and physical activity and we ask them to leave 2 test tubes of blood at their local urologist/health care center. The pilot study has recently been completed and evaluated and the remaining 7,500 men in the cohort will be included during 2007 and 2008. So far, we have a response rate of approximately 85% on the blood samples. The response rate for the questionnaire is approximately 80% (both in the web based and paper based versions combined). Genotyping and analysis will begin in the fall of 2008. Sample types: * EDTA whole blood * Plasma * DNA Number of sample donors: 5492 (sample collection completed)

Proper citation: KI Biobank - PROCAP (RRID:SCR_006038) Copy   

•   Source: SciCrunch Registry

http://ki.se/en/meb/cancer-of-the-prostate-in-sweden-caps

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on May 3rd,2023. We have completed the recruitment of this population-based prostate cancer case-control study, one of the largest prostate cancer case-control study populations available so far. This study population was recruited in two phases. The inclusion and exclusion criteria were the same for the first (CAPS1) and second phase (CAPS2), except for the timeframe. In total, 3,030 cases and 1,960 controls participated in CAPS donating blood samples and answering a questionnaire during 2001-2003. In addition we have detailed clinical information on all 3,000 cases. With data generated from CAPS we have 25 published papers and 10 manuscripts since 2004. During 2006 we completed a record linkage to the Cause of Death Registry to determine the cause of death for all participants. We could conclude that 347 of the cases in CAPS had died of prostate cancer. The CAPS study has provided data to several new studies on markers on prostate cancer progression. Sample types: * EDTA whole blood * DNA Number of sample donors: 5015 (sample collection completed)

Proper citation: Cancer of the Prostate in Sweden (CAPS) (RRID:SCR_006033) Copy   

•   Source: SciCrunch Registry

http://ki.se/imm/cefalo-studien

Saliva taken from participants in a study investigating the association between environmental exposures and brain tumors in children aged 7-19 years and the interaction between these risk factors and genetic polymorphisms, which may confer susceptibility to effects of exogenous agents. Sample types: * Saliva Number of sample donors: 886 (sample collection completed)

Proper citation: KI Biobank - CEFALO (RRID:SCR_006034) Copy   

•   Source: SciCrunch Registry

https://clinicaltrials.gov/ct2/show/NCT00014001

The NIMH-funded Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study was a nationwide public health-focused clinical trial that compared the effectiveness of older (first available in the 1950s) and newer (available since the 1990s) antipsychotic medications used to treat schizophrenia. These newer medications, known as atypical antipsychotics, cost roughly 10 times as much as the older medications. CATIE is the largest, longest, and most comprehensive independent trial ever done to examine existing therapies for this disease. Schizophrenia is a brain disorder characterized by hallucinations, delusions, and disordered thinking. The course of schizophrenia is variable, but usually is recurrent and chronic, often causing severe disability. Previous studies have shown that taking antipsychotic medications consistently is far more effective than taking no medicine and that the drugs are necessary to manage the disease. The aim of the CATIE study was to determine which medications provide the best treatment for schizophrenia. Additional information may be found by following the links, http://www.nimh.nih.gov/trials/practical/catie/index.shtml, http://www.clinicaltrials.gov/ct/show/NCT00014001?order=1

Proper citation: CATIE - Clinical Antipsychotic Trials in Intervention Effectiveness (RRID:SCR_005615) Copy   

•   Source: SciCrunch Registry

http://harvard.eagle-i.net/i/0000012e-0219-d555-b2b9-4d8780000000

Core facility that provides the following services: Clinical diagnosis services, Genomic sequencing service, ABI capillary sequencing service, Illumina next generation sequencing service, shRNA library sequencing service, High throughput genome sequencing, PCR to detection service, Plasmid sequencing service, Sequencing, Chip-Seq service, Digital Gene Expression Service, Nucleic acid library construction service, Next gen seq bioinformatics support service, Transcriptome and RNA-Seq service.

Proper citation: Harvard PCPGM DNA Sequencing Facility (RRID:SCR_009858) Copy   

•   Source: SciCrunch Registry

http://uccaribe.eagle-i.net/i/00000135-d3e6-439f-a272-8ee780000000

Core facility that provides the following services: Equipment support, Research software design. Is a core area housing major equipment such as ultracentrifuges, freezers, spectrophotometers, gamma counters, etc, as well as the centralized cell culture facility. The unit fosters equipment sharing, centralizes maintenance of equipment and provides repair for the equipment of all the projects.

Proper citation: UCC Common Instrumentation Area and Services (RRID:SCR_009851) Copy   

•   Source: SciCrunch Registry

http://harvard.eagle-i.net/i/0000012e-5870-e12d-55da-381e80000000

The Forsyth Center for Clinical and Translational Research (CCTR) is a unique clinical facility with 6 fully-equipped dental units and associated laboratories that are specifically dedicated to conduct clinical research in oral and related systemic diseases. Clinical trials following FDA guidelines are performed at all levels, from early phase 1 trials to large, multicenter definitive clinical trials, with the goal of improving outcomes and the long-term health of patients. We routinely conduct studies in the oral environment, that include standard clinical measurement protocols for dental caries, dental calculus, gingivitis, periodontal diseases, intraoral local anesthetic evaluation, tooth restoration and tooth whitening evaluation. In addition, the clinic is equipped for obtaining and processing microbiological samples, gingival crevice fluid samples, blood and saliva samples for analysis of bacteria, inflammatory mediators, as well as for genomic and proteomic analyses. Under the new leadership of Dr. Thomas Van Dyke, Vice President of Clinical Research at The Forsyth Institute, the Center proposes new goals/efforts in discovering new techniques, testing new ideas and searching for valuable biomarkers for preventing and treating periodontal diseases and associated systemic inflammatory conditions. The CCTR is actively involved with the design and conduct of clinical research under Good Clinical Practices for submission to regulatory agencies. It has a published international reputation in evaluating intraoral local drug delivery devices, oral diagnostic systems, local anesthesia, restorative materials, tooth whitening systems and the association of oral diseases with systemic conditions. Forsyth''s Institutional Review Board is a member of the Harvard Catalyst Regulatory Group and meets on a monthly basis providing complete review of clinical protocols.

Proper citation: Harvard Forsyth Center for Clinical and Translational Research (RRID:SCR_009847) Copy   

•   Source: SciCrunch Registry

http://harvard.eagle-i.net/i/0000012c-60a9-25c8-c437-ff0b80000000

Core facility that provides the following services: MLV plasmid construction service, HIV plasmid construction service, Adenovirus plasmid construction service. The Harvard Gene Therapy Initiative was founded with the objective of promoting the use of gene therapy in both research and therapeutic applications and to conduct research developing new gene delivery vector technologies.

Proper citation: Harvard Gene Therapy Initiative Core (RRID:SCR_009848) Copy   

•   Source: SciCrunch Registry

http://harvard.eagle-i.net/i/00000135-5ed7-550c-be1e-73c480000000

The Small Molecule Mass Spectrometry Facility at the FAS Center for Systems Biology offers support for the analysis of a wide variety of analytes using mass spectrometry based techniques. We are located in the second basement (B2) level of the Northwest Laboratory building at 52 Oxford Street, Cambridge, MA 02138. We provide services for molecular formula confirmation (accurate mass measurement), structural elucidation (MS/MS) and quantitation of small molecules. In addition, we can assist you in the mass analysis of a wide variety of non-proteomics samples including metabolites, medium sized proteins and oligonucleotides. Please contact us and tell us about your samples prior to submission or use of our Open Access laboratory.

Proper citation: Harvard FAS Small Molecule Mass Spectrometry Facility (RRID:SCR_009845) Copy   

•   Source: SciCrunch Registry

http://harvard.eagle-i.net/i/0000012e-a1a6-4291-55da-381e80000000

Core facility that provides the following services: Progamming and sequencing classes and training. Research Computing (RC) facilitates the advancement of complex research by providing leading edge computing services across the Faculty of Arts & Sciences (FAS). RC staff maintain expertise in constantly changing computing technologies, while ''speaking the language'' of the FAS researchers, to help them use computing more effectively.

Proper citation: Harvard FAS Research Computing Core (RRID:SCR_009844) Copy   

•   Source: SciCrunch Registry

http://harvard.eagle-i.net/i/0000012f-e9eb-c410-de5a-673e80000000

The Neuroimaging facility has a 3-Tesla magnetic resonance imaging scanner for non-invasive human brain imaging. Our aim is to: * Provide functional and anatomic magnetic resonance imaging (MRI) to scientists studying human cognition, brain development and aging, and individual differences * Provide training for undergraduate and graduate students destined to become the next generation of neuroscientists * Pioneer innovative ways of imaging the human brain and is a first adopter of new neuroimaging technology, tools and applications * Develop and make available the data processing and visualization tools demanded by advancing neuroimaging technologies.

Proper citation: Harvard FAS Center for Brain Science - Neuroimaging Core Facility (RRID:SCR_009842) Copy   

•   Source: SciCrunch Registry

http://harvard.eagle-i.net/i/0000012f-e9ed-31bd-de5a-673e80000000

CBS hosts an optical imaging facility that houses advanced devices for widespread use by neuroscientists and is developing the next generation of optical techniques. The optical imaging is intended to be an extension of individual labs, housed in shared space. By pooling equipment, highly skilled technical management of the tools is available, allowing for routine technological upgrades, quicker troubleshooting, and expert advice. In addition, the joint space leads to camaraderie amongst users, and allows new technical advances in one lab to spread rapidly to other labs. This core facility also frees up space in individual labs that can be used in other ways. Finally, the shared equipment lowers barriers to adoption of the latest technology. This core facility provides: * Laser scanning microscopes with motorized stages for high throughput reconstructions of the nervous system * A histology suite for brain sectioning and tissue preparation * Stereo fluorescence macroscopes * The newest tools for high-resolution optical microscopy * Ultra-fast optical scanning microscopes

Proper citation: Harvard FAS Center for Brain Science - Imaging Core Facility (RRID:SCR_009840) Copy   

•   Source: SciCrunch Registry